Amgen Shares Surge on Strong Earnings and Cardiovascular Drug Breakthrough
Published on 11/13/2025 at 09:07 | Redaktion boerse-global.de
Biotechnology leader Amgen is experiencing a significant rally, propelled by a powerful combination of exceptional financial performance and a major clinical achievement. The company’s latest quarterly report shattered forecasts, while groundbreaking trial data for its heart medication Repatha has generated substantial market optimism.
Amgen delivered a standout financial performance for the third quarter of 2025. The company reported earnings per share of $5.64, decisively beating analyst estimates by a notable 63 cents. Revenue growth was equally impressive, climbing 12.4% year-over-year to reach $9.56 billion. These results not only demonstrate the firm’s operational strength but also highlight its exceptional profitability, evidenced by a net margin approaching 19%.
Management’s confidence in the company’s Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
